|
δ
D
|
Diffusion coefficient of DCs
|
8.64×10−7 cm2 day−1
|
[65]
|
|
δ
T
|
Diffusion coefficient of T cells
|
8.64×10−7 cm2 day−1
|
[65]
|
|
δ
M
|
Diffusion coefficient of MDSCs
|
8.64×10−7 cm2 day−1
|
[65]
|
|
δ
C
|
Diffusion coefficient of tumor cells
|
8.64×10−7 cm2 day−1
|
[65]
|
|
\(\delta _{I_{12}}\)
|
Diffusion coefficient of IL-12
|
6.05×10−2 cm2 day−1
|
Estimated
|
|
\(\delta _{I_{2}}\)
|
Diffusion coefficient of IL-2
|
9.58×10−2 cm2 day−1
|
Estimated
|
|
\(\delta _{T_{\beta }}\)
|
Diffusion coefficient of TGF- β
|
8.52×10−2 cm2 day−1
|
Estimated
|
|
\(\delta _{I_{6}}\)
|
Diffusion coefficient of IL-6
|
9.03×10−2 cm2 day−1
|
Estimated
|
|
\(\delta _{I_{10}}\)
|
Diffusion coefficient of IL-10
|
9.11×10−2 cm2 day−1
|
Estimated
|
|
δ
A
|
Diffusion coefficient of anti-PD-1
|
7.85×10−2 cm2 day−1
|
Estimated
|
|
δ
B
|
Diffusion coefficient of BRAF/MEKi
|
3.16×10−1 cm2 day−1
|
Estimated
|
|
σ
0
|
Flux rate of T
1 and T
8 cells at the boundary
|
1 cm−1
|
[65]
|
|
χ
|
Chemoattraction coefficient of IL-6
|
10 cm5/g·day
|
[90, 91]
|
|
λ
DC
|
Activation rate of DCs by tumor cells
|
4 g/cm3·day
|
[65]
|
|
\(\lambda _{T_{1}I_{12}}\)
|
Activation rate of CD 4+ T cells by IL-12
|
18.64 day−1
|
Estimated
|
|
\(\lambda _{T_{1}I_{2}}\)
|
Activation rate of CD 4+ T cells by IL-2
|
0.25 day−1
|
[65]
|
|
\(\lambda _{T_{8}I_{12}}\)
|
Activation rate of CD 8+ T cells by IL-12
|
16.6 day−1
|
Estimated
|
|
\(\lambda _{T_{8}I_{2}}\)
|
Activation rate of CD 8+ T cells by IL-2
|
0.25 day−1
|
[65]
|
|
\(\lambda _{T_{r}T_{\beta }}\)
|
Activation rate of Tregs by TGF- β
|
0.415 day−1
|
Estimated
|
|
\(\lambda _{T_{r}Q}\)
|
Activation rate of Tregs by PD-1-PD-L1
|
0.083 day−1
|
Estimated
|
|
λ
M
|
Activation rate of MDSCs
|
1.05 day−1
|
[40]
|
|
λ
C
|
Growth rate of cancer cells
|
0.616 day−1
|
Estimated
|
|
λ
0
|
Growth rate of cancer cells uninhibited (by immune cells)
|
0.069 day−1
|
Estimated
|
|
\(\lambda _{I_{12}D}\)
|
Production rate of IL-12 by DCs
|
2.76×10−6 day−1
|
Estimated
|
|
\(\lambda _{I_{12}B}\)
|
Promotion of IL-12 production by BRAF/MEKi
|
1
|
Estimated
|
|
\(\lambda _{I_{2}T_{1}}\)
|
Production rate of IL-2 by CD 4+ T cells
|
2.82×10−8 day−1
|
Estimated
|
|
\(\lambda _{T_{\beta } C}\)
|
Production rate of TGF- β by cancer cells
|
2.18×10−10 day−1
|
Estimated
|
|
\(\lambda _{T_{\beta } T_{r}}\)
|
Production rate of TGF- β by Tregs
|
5.57×10−9 day−1
|
[75]
|
|
\(\lambda _{T_{\beta } M}\)
|
Production rate of TGF- β by MDSCs
|
2.18×10−10 day−1
|
Estimated
|
|
\(\lambda _{I_{6} C}\)
|
Production rate of IL-6 by cancer cells
|
3.54×10−10 day−1
|
Estimated
|
|
\(\lambda _{I_{10} C}\)
|
Production rate of IL-10 by cancer cells
|
9.10×10−10 day−1
|
Estimated
|
|
\(\lambda _{I_{10} M}\)
|
Production rate of IL-10 by MDSCs
|
1.82×10−9 day−1
|
Estimated
|
|
η
1
|
Killing rate of tumor cells by CD 4+ T cells
|
11.5 day−1·cm3/g
|
Estimated
|
|
η
8
|
Killing rate of tumor cells by CD 8+ T cells
|
46 day−1·cm3/g
|
Estimated
|
|
μ
PA
|
Blocking rate of PD-1 by anti-PD-1
|
6.04×106 cm3/g·day
|
Estimated
|
|
μ
BC
|
Absorbtion rate of BRAF/MEKi by cancer cells
|
6.17×10−10 day−1
|
Estimated
|
|
ρ
P
|
Expression of PD-1 in T cells
|
2.49×10−7
|
Estimated
|
|
ρ
L
|
Expression of PD-L1 in T cells
|
5.22×10−7
|
Estimated
|
|
ε
C
|
Expression of PD-L1 in tumor cells
|
0.01
|
[84]
|
|
ε
M
|
Expression of PD-L1 in MDSCs
|
0.005
|
Estimated
|
|
d
D
|
Death rate of DCs
|
0.1 day−1
|
[65]
|
|
\(d_{T_{1}}\)
|
Death rate of CD 4+ T cells
|
0.197 day−1
|
[65]
|
|
\(d_{T_{8}}\)
|
Death rate of CD 8+ T cells
|
0.18 day−1
|
[65]
|
|
\(d_{T_{r}}\)
|
Death rate of Tregs
|
0.2 day−1
|
[75]
|
|
d
M
|
Death rate of MDSCs
|
0.03 day−1
|
[40]
|
|
d
C
|
Death rate of tumor cells
|
0.17 day−1
|
[65]
|
|
\(d_{I_{12}}\)
|
Degradation rate of IL-12
|
1.38 day−1
|
[65]
|
|
\(d_{I_{2}}\)
|
Degradation rate of IL-2
|
2.376 day−1
|
[65]
|
|
\(d_{T_{\beta }}\)
|
Degradation rate of TGF- β
|
499.066 day−1
|
Estimated
|
|
\(d_{I_{6}}\)
|
Degradation rate of IL-6
|
4.16 day−1
|
Estimated
|
|
\(d_{I_{10}}\)
|
Degradation rate of IL-10
|
8.32 day−1
|
Estimated
|
|
d
A
|
Degradation rate of anti-PD-1
|
0.046 day−1
|
[87]
|
|
d
B
|
Degradation rate of BRAF/MEKi
|
1.66day−1
|
Estimated
|
|
D
0
|
Density of inactive DCs
|
2×10−5 g/cm3
|
[65]
|
|
T
10
|
Density of naive CD 4+ T cells in tumor
|
4×10−4 g/cm3
|
Estimated
|
|
T
80
|
Density of naive CD 8+ T cells in tumor
|
2×10−4 g/cm3
|
Estimated
|
|
C
M
|
Carrying capacity of cancer cells
|
0.8 g/cm3
|
[65]
|
|
\(\hat T_{1}\)
|
Density of CD 4+ T cells from lymph node
|
4×10−3 g/cm3
|
Estimated
|
|
\(\hat T_{8}\)
|
Density of CD 8+ T cells from lymph node
|
2×10−3 g/cm3
|
Estimated
|
